|
1
|
Ingle PV, Samsudin SZ, Chan PQ, Ng MK,
Heng LX, Yap SC, Chai AS and Wong AS: Development and novel
therapeutics in hepatocellular carcinoma: A review. Ther Clin Risk
Manag. 12:445–455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, Henley SJ, Cucinelli JE and
McGlynn KA: Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastroenterol.
109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li H, Wei Y, Li B and Peng B: The first
case of total laparoscopic living donor right hemihepatectomy in
mainland China and literature review. Surg Laparosc Endosc Percutan
Tech. 26:172–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu L, Shen F, Xia Y and Yang YF: Evolving
role of radiopharmaceuticals in hepatocellular carcinoma treatment.
Anticancer Agents Med Chem. 16:1155–1165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Navadgi S, Chang CC, Bartlett A, McCall J
and Pandanaboyana S: Systematic review and meta-analysis of
outcomes after liver resection in patients with hepatocellular
carcinoma (HCC) with and without bile duct thrombus. HPB (Oxford).
18:312–316. 2016. View Article : Google Scholar
|
|
6
|
Li YW, Yang FC, Lu HQ and Zhang JS:
Hepatocellular carcinoma and hepatitis B surface protein. World J
Gastroenterol. 22:1943–1952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu SJ: A concise review of updated
guidelines regarding the management of hepatocellular carcinoma
around the world: 2010–2016. Clin Mol Hepatol. 22:7–17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dost S, Baichoo E and Dieterich DT:
Chronic hepatitis B and C infection in the United States: A review
of current guidelines, disease burden and cost effectiveness of
screening. Expert Rev Anti Infect Ther. 14:511–521. 2016.
View Article : Google Scholar
|
|
9
|
Moirangthem A and Patel T: Mesenchymal
stem cell derived extracellular vesicles: A promising new
therapeutic approach for hepatic injury. Biotarget. 1:122017.
View Article : Google Scholar
|
|
10
|
Pascual S, Herrera I and Irurzun J: New
advances in hepatocellular carcinoma. World J Hepatol. 8:421–438.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taketomi A: Development and future
directions of antiangiogenic therapy in hepatocellular carcinoma.
Int J Clin Oncol. 21:2052016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Griffith OL, Griffith M, Krysiak K,
Magrini V, Ramu A, Skidmore ZL, Kunisaki J, Austin R, McGrath S,
Zhang J, et al: A genomic case study of mixed fibrolamellar
hepatocellular carcinoma. Ann Oncol. 27:1148–1154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li R, Yang D, Tang CL, Cai P, Ma KS, Ding
SY, Zhang XH, Guo DY and Yan XC: Combined hepatocellular carcinoma
and cholangiocarcinoma (biphenotypic) tumors: Clinical
characteristics, imaging features of contrast-enhanced ultrasound
and computed tomography. BMC Cancer. 16:1582016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu SC, Mato JM, Espinosa-Diez C and Lamas
S: Micro-RNA-mediated regulation of glutathione and methionine
metabolism and its relevance for liver disease. Free Radic Biol
Med. 100:66–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tornesello ML, Buonaguro L, Izzo F and
Buonaguro FM: Molecular alterations in hepatocellular carcinoma
associated with hepatitis B and hepatitis C infections. Oncotarget.
7:25087–25102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parasramka MA, Maji S, Matsuda A, Yan IK
and Patel T: Long non-coding RNAs as novel targets for therapy in
hepatocellular carcinoma. Pharmacol Ther. 161:67–78. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
D'Costa N, Chavez-Munoz C and So A: Role
of fibroblast growth factor receptor in sunitinib-resistant renal
cell carcinoma. Biotarget. 1:32017. View Article : Google Scholar
|
|
18
|
Liu YR, Tang RX, Huang WT, Ren FH, He RQ,
Yang LH, Luo DZ, Dang YW and Chen G: Long noncoding RNAs in
hepatocellular carcinoma: Novel insights into their mechanism.
World J Hepatol. 7:2781–2791. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gonzalez-Rodriguez A and Valverde AM: RNA
interference as a therapeutic strategy for the treatment of liver
diseases. Curr Pharm Des. 21:4574–4586. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie QY, Almudevar A, Whitney-Miller CL,
Barry CT and McCall MN: A microRNA biomarker of hepatocellular
carcinoma recurrence following liver transplantation accounting for
within-patient heterogeneity. BMC Med Genomics. 9:182016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee CH, Kim JH and Lee SW: The role of
microRNA in pathogenesis and as markers of HCV chronic infection.
Curr Drug Targets. 17:12016.
|
|
22
|
Fang Q, Xu T, Wu C, Zhou S and Sun H:
Biotargets in neural regeneration. Biotarget. 1:62017. View Article : Google Scholar
|
|
23
|
Afonso MB, Rodrigues PM, Simão AL and
Castro RE: Circulating microRNAs as potential biomarkers in
non-alcoholic fatty liver disease and hepatocellular carcinoma. J
Clin Med. 5:52016. View Article : Google Scholar
|
|
24
|
Wang L, Yue Y, Wang X and Jin H: Function
and clinical potential of microRNAs in hepatocellular carcinoma.
Oncol Lett. 10:3345–3353. 2015. View Article : Google Scholar
|
|
25
|
Mizuguchi Y, Takizawa T, Yoshida H and
Uchida E: Dysregulated miRNA in progression of hepatocellular
carcinoma: a systematic review. Hepatol Res. 46:391–406. 2016.
View Article : Google Scholar
|
|
26
|
Wang Q, Wei L, Guan X, Wu Y, Zou Q and Ji
Z: Briefing in family characteristics of microRNAs and their
applications in cancer research. Biochim Biophys Acta. 1844(1 Pt
B): 191–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaplan BB, Kar AN, Gioio AE and Aschrafi
A: MicroRNAs in the axon and presynaptic nerve terminal. Front Cell
Neurosci. 7:1262013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li M, Fu W, Wo L, Shu X, Liu F and Li C:
miR-128 and its target genes in tumorigenesis and metastasis. Exp
Cell Res. 319:3059–3064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leite-Moreira AM, Lourenço AP,
Falcão-Pires I and Leite-Moreira AF: Pivotal role of microRNAs in
cardiac physiology and heart failure. Drug Discov Today.
18:1243–1249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Piva R, Spandidos DA and Gambari R: From
microRNA functions to microRNA therapeutics: novel targets and
novel drugs in breast cancer research and treatment (Review). Int J
Oncol. 43:985–994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Palumbo S, Miracco C, Pirtoli L and
Comincini S: Emerging roles of microRNA in modulating cell-death
processes in malignant glioma. J Cell Physiol. 229:277–286. 2014.
View Article : Google Scholar
|
|
32
|
Zhang WC, Liu J, Xu X and Wang G: The role
of microRNAs in lung cancer progression. Med Oncol. 30:6752013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu JJ and Xia SJ: Novel role of microRNAs
in prostate cancer. Chin Med J (Engl). 126:2960–2964. 2013.
|
|
34
|
Wu Y and Jiang M: The revolution of lung
cancer treatment: From vaccines, to immune checkpoint inhibitors,
to chimeric antigen receptor T therapy. Biotarget. 1:72017.
View Article : Google Scholar
|
|
35
|
Lanaya H, Natarajan A, Komposch K, Li L,
Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic
M, et al: EGFR has a tumour-promoting role in liver macrophages
during hepatocellular carcinoma formation. Nat Cell Biol.
16:972–977. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Yao J, Shi X, Hu LL, Li ZF, Song
TS and Huang C: MicroRNA-302b suppresses cell proliferation by
targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells.
BMC Cancer. 13:4482013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang W, Zhang H, Wang L, Zhang S and Tang
M: miR-613 inhibits the growth and invasiveness of human
hepatocellular carcinoma via targeting DCLK1. Biochem Biophys Res
Commun. 473:987–992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou X, Zhu HQ, Ma CQ, Li HG, Liu FF,
Chang H and Lu J: miR-1180 promoted the proliferation of
hepatocellular carcinoma cells by repressing TNIP2 expression.
Biomed Pharmacother. 79:315–320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou W, Zhang C, Jiang H, Zhang Z, Xie L
and He X: miR-493 suppresses the proliferation and invasion of
gastric cancer cells by targeting RhoC. Iran J Basic Med Sci.
18:1027–1033. 2015.
|
|
40
|
Sakai H, Sato A, Aihara Y, Ikarashi Y,
Midorikawa Y, Kracht M, Nakagama H and Okamoto K: MKK7 mediates
miR-493-dependent suppression of liver metastasis of colon cancer
cells. Cancer Sci. 105:425–430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
42
|
Tzeng CW, Tzeng WS, Lin LT, Lee CW, Yen FL
and Lin CC: Enhanced autophagic activity of artocarpin in human
hepatocellular carcinoma cells through improving its solubility by
a nanoparticle system. Phytomedicine. 23:528–540. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mouli S, Hickey R, Thornburg B, Sato KT,
Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, et
al: Single-versus triple-drug chemoembolization for hepatocellular
carcinoma: Comparing outcomes by toxicity, imaging response, and
survival. J Vasc Interv Radiol. 27:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ren Y, Qiu L, Lü F, Ru X, Li S, Xiang Y,
Yu S and Zhang Y: TALENs-directed knockout of the full-length
transcription factor Nrf1α that represses malignant behaviour of
human hepatocellular carcinoma (HepG2) cells. Sci Rep. 6:237752016.
View Article : Google Scholar
|
|
45
|
Zhang D, Cao C, Liu L and Wu D:
Up-regulation of lncRNA SNHG20 predicts poor prognosis in
hepatocellular carcinoma. J Cancer. 7:608–617. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gao JZ, Li J, Du JL and Li XL: Long
non-coding RNA HOTAIR is a marker for hepatocellular carcinoma
progression and tumor recurrence. Oncol Lett. 11:1791–1798. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vira D, Basak SK, Veena MS, Wang MB, Batra
RK and Srivatsan ES: Cancer stem cells, microRNAs, and therapeutic
strategies including natural products. Cancer Metastasis Rev.
31:733–751. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Link A, Kupcinskas J, Wex T and
Malfertheiner P: Macro-role of microRNA in gastric cancer. Dig Dis.
30:255–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tambe M, Pruikkonen S, Mäki-Jouppila J,
Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE,
Davidson B, et al: Novel Mad2-targeting miR-493-3p controls mitotic
fidelity and cancer cells' sensitivity to paclitaxel. Oncotarget.
7:12267–12285. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Okamoto K, Ishiguro T, Midorikawa Y, Ohata
H, Izumiya M, Tsuchiya N, Sato A, Sakai H and Nakagama H: miR-493
induction during carcinogenesis blocks metastatic settlement of
colon cancer cells in liver. EMBO J. 31:1752–1763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Han Q, Hong Y, Fu Z, Zhang M, Cao X, Liu
Y, Ma S, Guo Y, Lu K, Zhu C, et al: Characterization of VAMP2 in
Schistosoma japonicum and the evaluation of protective efficacy
induced by recombinant SjVAMP2 in mice. PLoS One. 10:e01445842015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ropert N, Jalil A and Li D: Expression and
cellular function of vSNARE proteins in brain astrocytes.
Neuroscience. 323:76–83. 2016. View Article : Google Scholar
|
|
53
|
Kosiorek M, Zylinska L, Zablocki K and
Pikula S: Calcineurin/NFAT signaling represses genes Vamp1 and
Vamp2 via PMCA-dependent mechanism during dopamine secretion by
pheochromocytoma cells. PLoS One. 9:e921762014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mohankumar S and Patel T: Extracellular
vesicle long noncoding RNA as potential biomarkers of liver cancer.
Brief Funct Genomics. 15:249–256. 2016. View Article : Google Scholar :
|
|
55
|
Nie H, Cao Q, Zhu L, Gong Y, Gu J and He
Z: Acetylcholine acts on androgen receptor to promote the migration
and invasion but inhibit the apoptosis of human hepatocarcinoma.
PLoS One. 8:e616782013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rodrigues HA, Fonseca Mde C, Camargo WL,
Lima PM, Martinelli PM, Naves LA, Prado VF, Prado MA and Guatimosim
C: Reduced expression of the vesicular acetylcholine transporter
and neurotransmitter content affects synaptic vesicle distribution
and shape in mouse neuromuscular junction. PloS One. 8:e783422013.
View Article : Google Scholar : PubMed/NCBI
|
